Cognition Therapeutics Inc CGTX announces the publication of data from a Phase 1b SNAP study of CT1812 measuring Aβ oligomer displacement in Alzheimer’s disease Journal of Translational Neurodegeneration.

“By evaluating hourly changes in beta-amyloid (Aβ) oligomer concentrations in the cerebrospinal fluid (CSF) of individuals with mild to moderate Alzheimer’s disease, we were able to monitor the effects of CT1812 targeting,” said Mary Hamby, Vice President of Research .

“Data from the Phase 1b SNAP learn reflect the results of our preclinical studies showing the displacement of Aβ oligomers from neurons in culture and into the cerebrospinal fluid in transgenic mice,” added Hamby.

Results from the SNAP study show that a single oral dose of CT1812 rapidly displaces Aβ oligomers from synapses.

This was demonstrated by a significant increase in CSF-Aβ oligomer levels over time after a single dose of CT1812.

No change in Aβ oligomer levels was observed after placebo administration.

In this study of three subjects with Alzheimer’s disease, CT1812 was well tolerated and there were no serious adverse events related to the study medication, but rather related to the lumbar puncture of the indwelling catheter used for CSF sampling.

Price promotion: CGTX shares are up 14.70% at $2.00 at last check on Thursday.